<DOC>
	<DOCNO>NCT00421460</DOCNO>
	<brief_summary>The purpose study evaluate response treatment testosterone undecanoate determine level total free testosterone hypogonadal patient erectile dysfunction .</brief_summary>
	<brief_title>The Therapy Nebido Mono Combination With PDE-5 Inhibitors Hypogonadal Patients With Erectile Dysfunction</brief_title>
	<detailed_description>Hypogonadism pathophysiologic clinical factor substantial number patient ED , data indicate threshold level testosterone necessary normal erectile function.Testosterone therapy clearly indicate hypogonadal patient beneficial patient ED hypogonadism.However , testosterone efficacy monotherapy ED could limit , combination therapy testosterone ED treatment , PDE-5 inhibitor may valuable certain subpopulation patient .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>1 . Patients ED 3 month ( specify use IIEF score ) 2 . Age &gt; = 18 year . 3 . Stable sexual relationship 4 . With low low normal serum testosterone level ( either total bioavailable testosterone ) TT &lt; = 4 ng/ml and/or BT &lt; = 1 ng/ml 5 . Aging Male Symptom scale total score start 37 point ( must replace TT &lt; 4 ng/ml ) 6 . Eligible subject previously take oral androgen PDE5 inhibitor must discontinue use 1 month 1 . Contraindication treatment Testosterone accord SPC 2 . Hypersensitivity active substance excipients Nebido 3 . Diagnosed suspected carcinoma prostate male breast cancer 4 . Past present liver tumor 5 . Acute chronic hepatic disease 6 . Severe cardiac , hepatic renal insufficiency 7 . History penile implant significant penile deformity 8 . Diagnosed sleep apnea 9 . Polycythemia ( Hematocrit &gt; 50 % ) 10 . Prolactin &gt; 25 ng/ml 11 . Organic hypothalamicpituitary pathology 12 . Any unstable medical , psychiatric drug/alcohol abuse disorder 13 . Prostate specific antigen ( PSA ) &gt; = 4 ng/ml 14 . Severe symptomatic benign prostatic hyperplasia ( IPSS ) sum score &gt; =20 ) 15 . Diabetes mellitus uncontrolled ( HbAlc level &gt; 10 % ) 16 . Epilepsy adequately control treatment 17 . Patients require fertility treatment 18 . Hypertension adequately control therapy 19 . Clinically significant chronic hematological disease may lead priapism sickle cell anemia , multiple myeloma leukemia 20 . Hypersensitivity PDE5 inhibitor 21 . Concomitant Medication : Nitrites Nitric oxide donor Antiandrogens anticoagulant , exception antiplatelet agent Any potent inhibitor cytochrome P450 3A4 : HIV protease inhibitor ( Ritonavir Indinavir ) ; Antimycotic agent ( Itraconazole Ketoconazole ) topical application allow ; Erythromycin .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Nebido hypogonadism erectile dysfunction</keyword>
</DOC>